CSHNX
Price
$12.65
Change
+$0.20 (+1.61%)
Updated
Jun 2 closing price
Net Assets
1.2B
PRPQX
Price
$7.18
Change
+$0.11 (+1.56%)
Updated
Jun 2 closing price
Net Assets
551.7M
Interact to see
Advertisement

CSHNX vs PRPQX

Header iconCSHNX vs PRPQX Comparison
Open Charts CSHNX vs PRPQXBanner chart's image
CSHNX vs PRPQX Comparison Chart in %
View a ticker or compare two or three
VS
CSHNX vs. PRPQX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSHNX is a StrongBuy and PRPQX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CSHNX has more cash in the bank: 1.2B vs. PRPQX (552M). PRPQX pays higher dividends than CSHNX: PRPQX (8.31) vs CSHNX (5.83). CSHNX was incepted earlier than PRPQX: CSHNX (12 years) vs PRPQX (8 years). CSHNX (1.46) is less costly to investors than PRPQX (1.11). CSHNX is a more actively managed with annual turnover of: 31.00 vs. PRPQX (21.00). PRPQX has a lower initial minimum investment than CSHNX: PRPQX (0) vs CSHNX (2500). PRPQX annual gain was more profitable for investors over the last year : 21.96 vs. CSHNX (19.48). CSHNX return over 5 years is better than : 151.63 vs. PRPQX (120.36).
CSHNXPRPQXCSHNX / PRPQX
Total Expense Ratio1.461.11132%
Annual Report Gross Expense Ratio1.461.11132%
Fund Existence12 years8 years-
Gain YTD23.74318.104131%
Front Load5%N/A-
Min. Initial Investment25000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.2B552M218%
Annual Yield % from dividends5.838.3170%
Returns for 1 year19.4821.9689%
Returns for 3 years95.3686.44110%
Returns for 5 years151.63120.36126%
Returns for 10 years93.21N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CMI672.6729.17
+4.53%
Cummins
PLUG4.090.15
+3.81%
Plug Power
HLF11.990.09
+0.76%
Herbalife Ltd
UTSI2.74-0.04
-1.53%
UTStarcom Holdings Corp
NVCT9.52-0.23
-2.36%
Nuvectis Pharma